Developer docs
API playgroundTry for free, no card

Search company profiles

Integro Theranostics

Full company profile

uuid00rxwox

Namestring
Integro Theranostics
Legal namestring
Integro Theranostics
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Integro Theranostics is a clinical-stage private biotechnology company developing an intraoperative molecular imaging (IMI) platform to help surgeons visualize cancer in real time during tumor resection surgery. The platform is built around two co-developed core products: Cronexitide Lanocianine (CXL, formerly LS301), a fluorescent imaging agent consisting of a small peptide conjugated to a near-infrared dye that binds to activated Annexin A2 protein expressed on cancer cells, and the CancerVision Goggles, a wearable head-mounted mixed-reality display that overlays CXL fluorescence signals onto the surgeon's natural-color field of view. Together, these products are designed to enable identification of cancer margins, microscopic tumors, and sentinel lymph nodes that are invisible to the naked eye, with the explicit goal of reducing positive margins and repeat surgeries.

The technology stack is anchored by Dr. Samuel Achilefu's research at Washington University School of Medicine's Mallinckrodt Institute, Molecular Imaging Center, and Siteman Cancer Center, and now extends to UT Southwestern Medical Center where Dr. Achilefu serves as inaugural Chair of Biomedical Engineering. An AI/analytics layer is layered on top through a partnership with OmniScience, providing computer vision workflows for deep tissue and intraoperative pathology assessment, predictive analytics for cancer spread, and data-driven clinical decision support across pre-, intra-, and post-operative imaging. The company holds 65 U.S. patents covering both the imaging agent and the wearable display, with CXL currently advancing through a Phase II lung cancer study initiated in late 2025 after positive Phase 1b results (NCT05900986 covers an ongoing breast cancer Phase 1b/2).

Integro Theranostics is a portfolio company of Kingdom Capital, a values-driven private investment firm whose founder Dave Steward also chairs World Wide Technology. The company's primary customer segments are hospitals and surgical centers performing cancer resection surgery, with secondary exposure to oncology clinical trial sponsors via the OmniScience AI tooling. Forward-looking revenue mechanics consist of single-use CXL imaging agent sales on a per-procedure basis paired with reusable CancerVision Goggles hardware sales to healthcare institutions, though no commercial pricing is disclosed and the company is not yet generating revenue. Strategic communications are concentrated in scientific publications, surgical and oncology conferences, and targeted press releases rather than consumer marketing channels.

Short descriptiontext

Integro Theranostics is a clinical-stage biotech developing an intraoperative molecular imaging platform for cancer surgery, combining the CXL fluorescent imaging agent, CancerVision Goggles, and AI analytics to help surgeons visualize tumors in real time.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intraoperative molecular imaging, fluorescent cancer imaging, surgical imaging agents, augmented reality surgery, fluorescence-guided oncology
Industry4 codes
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Imaging Agents and Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CXL Fluorescent Imaging Agent
TypeOne Time License
Description

Cronexitide Lanocianine (CXL) is administered to patients prior to surgery, providing a single-use per procedure revenue stream. The imaging agent is supplied to hospitals and surgical centers as a pharmaceutical product integrated into surgical care workflows.

2CancerVision Goggles
TypeHardware Sales
Description

Wearable medical device sold to hospitals and surgical centers for use in cancer surgery. Provides reusable hardware revenue opportunity alongside consumable imaging agent sales.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1CXL (Cronexitide Lanocianine)
Description

A novel fluorescing molecule that binds to and illuminates cancer tissue, formerly known as LS301. A targeted fluorescent imaging agent for intraoperative molecular imaging during cancer surgery.

integrotheranostics.com
+1 more record
Core offering1 text field

Integro Theranostics develops an intraoperative molecular imaging (IMI) platform combining a fluorescent imaging agent (Cronexitide Lanocianine, CXL) with a wearable augmented reality display (CancerVision Goggles) and AI-powered analysis tools. The platform enables surgeons to visualize cancer cells, tumor margins, and lymph nodes in real time during oncologic surgery, particularly for lung and breast cancer procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 48% of 23 patients in Phase 1b study had previously undetected or unseen cancer lesions (Clinically Significant Events) identified using CXL
+2 more records
Product overview1 text field

Integro Theranostics is a clinical-stage company developing an intraoperative molecular imaging (IMI) platform for cancer surgery guidance. The platform combines two core products: CXL (Cronexitide Lanocianine), a fluorescent imaging agent that binds to and illuminates cancer tissue when exposed to near-infrared light, and the proprietary CancerVision Goggles, a wearable augmented reality display that visualizes the fluorescent signal overlaid on natural color imagery during surgery. Together, these products enable surgeons to identify cancer margins and lymph nodes in real-time, improving precision and completeness of tumor resection. The company also offers AI-powered solutions developed in partnership with OmniScience for computer vision-based cancer detection and clinical decision support.

Product and service3 records
1CXL (Cronexitide Lanocianine) Fluorescent Imaging Agent
CategoryFluorescent Imaging Agent (Pharmaceutical)
Description

A novel fluorescent imaging agent consisting of a small peptide and near-infrared (NIR) dye that binds to the activated form of Annexin A2 on cancer cells, enabling real-time visualization of tumors, cancer margins, and lymph nodes during oncologic surgery. Administered to patients prior to surgery and supplied to hospitals and surgical centers as a single-use pharmaceutical per procedure.

2CancerVision Goggles
CategoryWearable Medical Device (Hardware)
Description

A wearable head-mounted mixed reality display system that overlays CXL fluorescence images onto the surgeon's natural color field of view in real time. Enables surgeons to visualize cancer cells, identify microscopic tumors, assess surgical margins, and identify sentinel lymph nodes during cancer resection surgery without disrupting operating room workflow.

3AI-Powered Clinical Decision Support Solutions
CategoryAI Clinical Decision Support
Description

AI-powered computer vision workflows developed in partnership with OmniScience that enable deep tissue analysis at gross and microscopic scales, fluorescence characterization of tissue types, intraoperative pathology assessment, pattern identification, and predictive analytics for cancer clinical trials. Aggregates pre-, intra-, and post-operative imaging data to deliver data-driven clinical decision support.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Integro Theranostics was born out of collaboration between Kingdom Capital and Washington University School of Medicine. Dr. Achilefu developed CXL and CancerVision Goggles technology at Washington University's Mallinckrodt Institute, Molecular Imaging Center, and Siteman Cancer Center.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership to optimize cancer clinical trials using AI-powered computer vision workflows. OmniScience is developing advanced analytics for deep tissue analysis at gross and microscopic scales and fluorescence characterization of tissue types. The collaboration enables intraoperative pathology assessment through computer vision.

Strategic tierSupportingTypeTechnology or Integration
Description

World Wide Technology, the largest Black-owned company in the U.S., is supporting Integro's technology needs through software, cloud computing, and data resources. WWT is founded by Dave Steward, who also chairs Kingdom Capital.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Dr. Samuel Achilefu serves as the inaugural Chair of the Department of Biomedical Engineering at UT Southwestern Medical Center, where he continues research activities while serving as Integro's Chief Scientific Officer.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of OTIS (Optical Coherence Tomography Imaging System) for intraoperative margin assessment during breast-conserving surgery. Addresses the same surgical margin problem as Integro via a complementary imaging modality.

TypeEmerging player
Description

Developer of augmented reality surgical visualization platforms for use in operating rooms. Overlaps with Integro's CancerVision Goggles in wearable AR-mediated surgical guidance, though Medivis focuses on anatomical rather than fluorescent visualization.

TypeEmerging player
Description

Provider of VR/AR-based surgical visualization and planning tools. Adjacent competitor in immersive surgical visualization technology with overlapping enterprise hospital sales channels.

TypeDirect peer
Description

Developer of Lumisight (pegulicianine), an FDA-approved fluorescent imaging agent for breast cancer lumpectomy margin assessment. Most direct competitor to Integro's CXL, addressing the same intraoperative cancer visualization problem in an overlapping indication.

TypeEmerging player
Description

Developer of ActivSight intraoperative imaging software providing real-time visual overlays of perfusion and other tissue characteristics. An emerging adjacent player in AR/computer-vision-enhanced surgery with comparable design intent to CancerVision Goggles.

TypeBroad incumbent
Description

Manufacturer of the Da Vinci surgical robot with integrated Firefly fluorescence imaging. Represents a broad incumbent in fluorescence-guided minimally invasive surgery whose installed base shapes how new agents like CXL gain OR access.

TypeDirect peer
Description

Developer of Cytalux (pafolacianine), an FDA-approved fluorescent imaging agent targeting folate receptor-expressing cancers including ovarian and lung. Directly comparable to CXL as a targeted fluorescent agent for intraoperative cancer visualization.

TypeBroad incumbent
Description

Large medtech incumbent offering SPY-PHI and SPY-Fi fluorescence imaging systems integrated into surgical workflows across multiple specialties. Competes broadly in fluorescence-guided surgery infrastructure that may be used alongside or against agent-based approaches like Integro's.

TypeEmerging player
Description

Developer of intraoperative surgical guidance and soft-tissue marker systems for oncology procedures, including breast and soft-tissue tumor localization. Compares to Integro on the broader theme of improving surgical precision in cancer resection workflows.

TypeDirect peer
Description

Developer of Tumor Paint (BLZ-100), a tumor-targeted fluorescent imaging agent for fluorescence-guided cancer surgery. Competes in the same intraoperative molecular imaging category as Integro's CXL platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Integro Theranostics

Surgical Imaging Agents and Devicesintegrotheranostics.com

Integro Theranostics is a clinical-stage biotech developing an intraoperative molecular imaging platform for cancer surgery, combining the CXL fluorescent imaging agent, CancerVision Goggles, and AI analytics to help surgeons visualize tumors in real time.

What Integro Theranostics does

Integro Theranostics is a clinical-stage private biotechnology company developing an intraoperative molecular imaging (IMI) platform to help surgeons visualize cancer in real time during tumor resection surgery. The platform is built around two co-developed core products: Cronexitide Lanocianine (CXL, formerly LS301), a fluorescent imaging agent consisting of a small peptide conjugated to a near-infrared dye that binds to activated Annexin A2 protein expressed on cancer cells, and the CancerVision Goggles, a wearable head-mounted mixed-reality display that overlays CXL fluorescence signals onto the surgeon's natural-color field of view. Together, these products are designed to enable identification of cancer margins, microscopic tumors, and sentinel lymph nodes that are invisible to the naked eye, with the explicit goal of reducing positive margins and repeat surgeries.

The technology stack is anchored by Dr. Samuel Achilefu's research at Washington University School of Medicine's Mallinckrodt Institute, Molecular Imaging Center, and Siteman Cancer Center, and now extends to UT Southwestern Medical Center where Dr. Achilefu serves as inaugural Chair of Biomedical Engineering. An AI/analytics layer is layered on top through a partnership with OmniScience, providing computer vision workflows for deep tissue and intraoperative pathology assessment, predictive analytics for cancer spread, and data-driven clinical decision support across pre-, intra-, and post-operative imaging. The company holds 65 U.S. patents covering both the imaging agent and the wearable display, with CXL currently advancing through a Phase II lung cancer study initiated in late 2025 after positive Phase 1b results (NCT05900986 covers an ongoing breast cancer Phase 1b/2).

Integro Theranostics is a portfolio company of Kingdom Capital, a values-driven private investment firm whose founder Dave Steward also chairs World Wide Technology. The company's primary customer segments are hospitals and surgical centers performing cancer resection surgery, with secondary exposure to oncology clinical trial sponsors via the OmniScience AI tooling. Forward-looking revenue mechanics consist of single-use CXL imaging agent sales on a per-procedure basis paired with reusable CancerVision Goggles hardware sales to healthcare institutions, though no commercial pricing is disclosed and the company is not yet generating revenue. Strategic communications are concentrated in scientific publications, surgical and oncology conferences, and targeted press releases rather than consumer marketing channels.

Integro Theranostics firmographics

Firmographics
Name
Integro Theranostics
Legal name
Integro Theranostics
Website
https://integrotheranostics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Integro Theranostics is a clinical-stage biotech developing an intraoperative molecular imaging platform for cancer surgery, combining the CXL fluorescent imaging agent, CancerVision Goggles, and AI analytics to help surgeons visualize tumors in real time.
Ownership category
akta.pro rank

Integro Theranostics industry classification

Industry
Product category
Surgical Imaging Agents and Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Intraoperative molecular imaging
  • Fluorescent cancer imaging
  • Surgical imaging agents
  • Augmented reality surgery
  • Fluorescence-guided oncology

Where Integro Theranostics is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Integro Theranostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. CXL Fluorescent Imaging Agent: Cronexitide Lanocianine (CXL) is administered to patients prior to surgery, providing a single-use per procedure revenue stream. The imaging agent is supplied to hospitals and surgical centers as a pharmaceutical product integrated into surgical care workflows.
  2. CancerVision Goggles: Wearable medical device sold to hospitals and surgical centers for use in cancer surgery. Provides reusable hardware revenue opportunity alongside consumable imaging agent sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Integro Theranostics product offering

Product offering

Core offering

Integro Theranostics develops an intraoperative molecular imaging (IMI) platform combining a fluorescent imaging agent (Cronexitide Lanocianine, CXL) with a wearable augmented reality display (CancerVision Goggles) and AI-powered analysis tools. The platform enables surgeons to visualize cancer cells, tumor margins, and lymph nodes in real time during oncologic surgery, particularly for lung and breast cancer procedures.

Product overview

Integro Theranostics is a clinical-stage company developing an intraoperative molecular imaging (IMI) platform for cancer surgery guidance. The platform combines two core products: CXL (Cronexitide Lanocianine), a fluorescent imaging agent that binds to and illuminates cancer tissue when exposed to near-infrared light, and the proprietary CancerVision Goggles, a wearable augmented reality display that visualizes the fluorescent signal overlaid on natural color imagery during surgery. Together, these products enable surgeons to identify cancer margins and lymph nodes in real-time, improving precision and completeness of tumor resection. The company also offers AI-powered solutions developed in partnership with OmniScience for computer vision-based cancer detection and clinical decision support.

Differentiator

Problem solved

Functional benefit

Brands

  • CXL (Cronexitide Lanocianine): A novel fluorescing molecule that binds to and illuminates cancer tissue, formerly known as LS301. A targeted fluorescent imaging agent for intraoperative molecular imaging during cancer surgery.
  • CancerVision Goggles

Products and services

  • CXL (Cronexitide Lanocianine) Fluorescent Imaging Agent A novel fluorescent imaging agent consisting of a small peptide and near-infrared (NIR) dye that binds to the activated form of Annexin A2 on cancer cells, enabling real-time visualization of tumors, cancer margins, and lymph nodes during oncologic surgery. Administered to patients prior to surgery and supplied to hospitals and surgical centers as a single-use pharmaceutical per procedure.
  • CancerVision Goggles A wearable head-mounted mixed reality display system that overlays CXL fluorescence images onto the surgeon's natural color field of view in real time. Enables surgeons to visualize cancer cells, identify microscopic tumors, assess surgical margins, and identify sentinel lymph nodes during cancer resection surgery without disrupting operating room workflow.
  • AI-Powered Clinical Decision Support Solutions AI-powered computer vision workflows developed in partnership with OmniScience that enable deep tissue analysis at gross and microscopic scales, fluorescence characterization of tissue types, intraoperative pathology assessment, pattern identification, and predictive analytics for cancer clinical trials. Aggregates pre-, intra-, and post-operative imaging data to deliver data-driven clinical decision support.

Quantifiable outcome

  • 48% of 23 patients in Phase 1b study had previously undetected or unseen cancer lesions (Clinically Significant Events) identified using CXL
  • +2 more outcomes

Companies that use Integro Theranostics

Customer profile

Segments3 records

Ideal customer profiles2 records

Integro Theranostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Integro Theranostics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Washington University School of MedicinecoreStrategic or Co-development PartnerIntegro Theranostics was born out of collaboration between Kingdom Capital and Washington University School of Medicine. Dr. Achilefu developed CXL and CancerVision Goggles technology at Washington University's Mallinckrodt Institute, Molecular Imaging Center, and Siteman Cancer Center.
  • OmniSciencecoreTechnology or IntegrationPartnership to optimize cancer clinical trials using AI-powered computer vision workflows. OmniScience is developing advanced analytics for deep tissue analysis at gross and microscopic scales and fluorescence characterization of tissue types. The collaboration enables intraoperative pathology assessment through computer vision.
  • World Wide Technology (WWT)supportingTechnology or IntegrationWorld Wide Technology, the largest Black-owned company in the U.S., is supporting Integro's technology needs through software, cloud computing, and data resources. WWT is founded by Dave Steward, who also chairs Kingdom Capital.
  • UT Southwestern Medical CentersupportingStrategic or Co-development PartnerDr. Samuel Achilefu serves as the inaugural Chair of the Department of Biomedical Engineering at UT Southwestern Medical Center, where he continues research activities while serving as Integro's Chief Scientific Officer.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Integro Theranostics competitors and assessment

Company assessment

Direct peers

  • Perimeter Medical Imaging AI: Developer of OTIS (Optical Coherence Tomography Imaging System) for intraoperative margin assessment during breast-conserving surgery. Addresses the same surgical margin problem as Integro via a complementary imaging modality.
  • Lumicell: Developer of Lumisight (pegulicianine), an FDA-approved fluorescent imaging agent for breast cancer lumpectomy margin assessment. Most direct competitor to Integro's CXL, addressing the same intraoperative cancer visualization problem in an overlapping indication.
  • On Target Laboratories: Developer of Cytalux (pafolacianine), an FDA-approved fluorescent imaging agent targeting folate receptor-expressing cancers including ovarian and lung. Directly comparable to CXL as a targeted fluorescent agent for intraoperative cancer visualization.
  • Blaze Bioscience: Developer of Tumor Paint (BLZ-100), a tumor-targeted fluorescent imaging agent for fluorescence-guided cancer surgery. Competes in the same intraoperative molecular imaging category as Integro's CXL platform.

Emerging players

  • Medivis: Developer of augmented reality surgical visualization platforms for use in operating rooms. Overlaps with Integro's CancerVision Goggles in wearable AR-mediated surgical guidance, though Medivis focuses on anatomical rather than fluorescent visualization.
  • Surgical Theater: Provider of VR/AR-based surgical visualization and planning tools. Adjacent competitor in immersive surgical visualization technology with overlapping enterprise hospital sales channels.
  • Activ Surgical: Developer of ActivSight intraoperative imaging software providing real-time visual overlays of perfusion and other tissue characteristics. An emerging adjacent player in AR/computer-vision-enhanced surgery with comparable design intent to CancerVision Goggles.
  • Elucent Medical: Developer of intraoperative surgical guidance and soft-tissue marker systems for oncology procedures, including breast and soft-tissue tumor localization. Compares to Integro on the broader theme of improving surgical precision in cancer resection workflows.

Broad incumbents

  • Intuitive Surgical: Manufacturer of the Da Vinci surgical robot with integrated Firefly fluorescence imaging. Represents a broad incumbent in fluorescence-guided minimally invasive surgery whose installed base shapes how new agents like CXL gain OR access.
  • Stryker: Large medtech incumbent offering SPY-PHI and SPY-Fi fluorescence imaging systems integrated into surgical workflows across multiple specialties. Competes broadly in fluorescence-guided surgery infrastructure that may be used alongside or against agent-based approaches like Integro's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Integro Theranostics social profiles

Digital presence

Integro Theranostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Integro Theranostics leadership team

Management profile

Number of profiles

Profiles9 records

Integro Theranostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Integro Theranostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integro Theranostics

What does Integro Theranostics do?

Integro Theranostics develops an intraoperative molecular imaging (IMI) platform combining a fluorescent imaging agent (Cronexitide Lanocianine, CXL) with a wearable augmented reality display (CancerVision Goggles) and AI-powered analysis tools. The platform enables surgeons to visualize cancer cells, tumor margins, and lymph nodes in real time during oncologic surgery, particularly for lung and breast cancer procedures.

Is Integro Theranostics a public or private company?

Integro Theranostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Integro Theranostics founded?

Integro Theranostics was founded in 2020. It employs 1 to 10 people.

Where is Integro Theranostics based?

Integro Theranostics is headquartered in St Louis, United States, in the North America region.

How does Integro Theranostics make money?

Two revenue lines are on record. CXL Fluorescent Imaging Agent is the primary driver. The others are cancerVision Goggles.

Who are Integro Theranostics's main competitors?

Direct peers on record are Perimeter Medical Imaging AI, Lumicell, On Target Laboratories and Blaze Bioscience. Emerging players are Medivis, Surgical Theater, Activ Surgical and Elucent Medical. Broad incumbents are Intuitive Surgical and Stryker.

Does Integro Theranostics have an API?

No public API is recorded for Integro Theranostics.

What industry is Integro Theranostics in?

Integro Theranostics's product category is Surgical Imaging Agents and Devices. Its primary akta.pro industry code is HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales